Podcasts about mgus

Episode InfoJeff Radke is CEO and Co-Founder of Accelerant, a technology-fueled insurance platform that empowers MGUs to more effectively and confidently serve small and medium enterprises. He has spent his career working across all areas of the insurance value chain, from underwriting to reinsurance in global markets. Prior to Accelerant, Jeff spent a decade at Argo Group International Holdings, but he became frustrated with thelegacy system's antiquated technology and emphasis on maintaining their position in the value chain over doing right by the customer. This inspired him to co-found Accelerant to enable data-driven innovation and collaboration that puts customers first. Accelerant rebuilds the way that underwriters share and exchange risk to improve outcomes for everyone, with a focus on the SMBs that power our global economy and their niche insurance needs. Jeff was previously a guest on the show, and you can catch that episode here. Episode Overview: Accelerant's IPO Journey: Successful Public Offering: Accelerant completed its Initial Public Offering (IPO) in July 2025. Timing Was Right: Radke believes the IPO occurred at the opportune moment, as the business model had become clearly defined and demonstrable to investors. He suggests it couldn't have happened much sooner. Market Conditions: The market timing for the IPO was favorable. Long-Term Vision: The IPO supports a long-term strategy, with the company prioritizing a 5-10-15 year horizon rather than short-term quarterly results. This contrasts with some other tech IPOs that focus on immediate performance. Investor Communication: Transparency with investors about expectations is crucial, and the company runs the business for the benefit of its customers and platform participants. Learning Experience: The post-IPO period, including initial market reactions and earnings announcements, served as a valuable, albeit challenging, reminder to focus on running the business exceptionally well and managing investor expectations. Accelerant's Mission & Problem Solved: Addresses a gap in the market for specialized underwriting talent moving to MGAs without adequate support. Recognizes the shift of risk retention to larger insurance companies, leaving a need for capacity. The Accelerant Platform: Aims to be the "rails" for specialty insurance. Focuses on: Smooth, transparent data flow. Efficiently connecting MGAs to risk capital. Leveraging technology and AI for data analytics and portfolio management. Growth & Key Initiatives: Serves 265 MGA members and partners with 17 insurance companies and 90+ capital providers. Mission: An Accelerant-owned entity providing a safety net and support for underwriters transitioning to MGAs. Risk Exchange: Facilitates capital matching for underwriters, with a focus on long-term network effects and data growth. The Evolving MGA Landscape: MGAs are growing significantly faster than the broader industry. Technology is enabling specialization and a "handoff" model across the value chain. This disaggregation is a natural progression, mirroring trends in other industries. Specialized coverage is increasingly in demand due to the complexity of modern businesses. Addressing Industry Inefficiencies: Identifies high expenses in areas like claims, underwriting, and actuarial functions as a key challenge. Advocates for mutualizing these expenses through centralized, technology-driven platforms like the Risk Exchange. Contrasts this with the traditional model where many companies perform the same functions sub-optimally. Differentiating Accelerant: Focuses on long-term viability and underwriting expertise, not just hype. Prioritizes serving members and capital partners with a service-minded approach. Offers a more efficient and effective alternative to traditional and some other insurtech models. This episode is brought to you by The Future of Insurance book series (future-of-insurance.com) from Bryan Falchuk. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.

"[Multiple myeloma] is very treatable, very manageable, but right now it is still considered an incurable disease. So, patients are on this journey with myeloma for the long term. It's very important for us to realize that during their journey, we will see them repeatedly. They are going to be part of our work family. They will be with us for a while. I think it's our job to be their advocate. To be really focused on not just the disease, but periodically assessing that financial burden and psychosocial aspect," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 16, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the pathophysiology and diagnosis of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 332: Best Nursing Practices for Pain Management in Patients With Cancer Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 192: Oncologic Emergencies 101: Hypercalcemia of Malignancy ONS Voice articles: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications Cancer Mortality Declines Among Black Patients but Remains Disproportionately High Financial Navigation During Hematologic Cancer Saves Patients and Caregivers $2,500 Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment Diagnose and Treat Hypercalcemia of Malignancy ONS books: BMTCN® Certification Review Manual (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing articles: African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities Music Intervention: Nonpharmacologic Method to Reduce Pain and Anxiety in Adult Patients Undergoing Bone Marrow Procedures Other ONS resources: Financial Toxicity Huddle Card Hypercalcemia of Malignancy Huddle Card Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Cancer Society article: What Is Multiple Myeloma? Blood Cancer United educational resources page International Myeloma Foundation homepage Myeloma University homepage Multiple Myeloma Research Foundation (MMRF) article: Understanding Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Epidemiologically, myeloma is a cancer of older adults. The median age is about 69. It is more common in men than women. It's a ratio of about three men to two women that are diagnosed. It is much more common in people of African American descent with increasing global incidence linked to aging populations. Although, the highest rates are in high-income countries. So, if we look at some of the risk factors, and several have been identified, including MGUS. MGUS is a benign precursor of myeloma, and it stands for monoclonal gammopathy of undetermined significance. Older age is also a risk factor, although we do see patients that are younger who are diagnosed with myeloma." TS 1:54 "Bone pain, specifically in the back, and fatigue, are very common symptoms that relate to things that are going on behind the scenes with myeloma. But also, patients can be bothered by frequent and long-lasting infections. So, they find that they get sick more frequently than their family and friends, and they take a longer time to recover. That could also be a presenting sign. I think there can be some presenting signs and symptoms related to electrolyte abnormalities, especially in later stages. They might be nauseated, vomiting, or constipated. Also, signs and symptoms related to cytopenias. You have to remember that this is a bone marrow cancer. So, we do have some problem with development of normal blood cells. So, we can see not only infections, but bleeding issues related to thrombocytopenia and factors related to anemia from low red blood cell counts." TS 7:15 "About 20%–25% of our patients who are diagnosed are asymptomatic. They have no symptoms. They're living their lives, they're going to work or they're traveling, playing golf on the weekends, taking care of their children or grandchildren. They are just living their lives. And at times, they go to the primary care physician and then they're referred to a hematologist-oncologist, and they're pretty surprised when they're sent to a cancer center. The way they are diagnosed in this matter is that their routine lab work, the complete blood cell count may be normal, there may be some slight differences in their hemoglobin. But what we see in the chemistry, the complete metabolic panel, is an elevation in their total protein and or an elevation of the total globulins." TS 9:22 "The bone marrow biopsy serves many purposes. You want to determine the percentage of bone marrow plasma cells. So, you want to get the degree of plasmacytosis. And then you want to do really specific tests on those plasma cells. So, you want to isolate the malignant plasma cells and determine, via analysis. So, we do the karyotype, chromosomal studies, fluorescence in situ hybridization (FISH) studies, immunohistochemistry studies, and molecular studies. All of these studies are looking for specific genetic changes in the myeloma cells—looking for translocations or deletions. And it's very important to get that information because we can put patients in a category of having standard-risk disease versus high-risk disease. And that can give us a better picture of what this patient's journey with myeloma may look like." TS 13:41 "When I used to work in lymphoma, I spoke with the physicians who were lymphoma specialists, and they said that they foresee a future in having these assays that detect circulating tumor cells actually take the place of imaging studies like restaging positron-emission tomography (PET), computed tomography (CT) scans. So, it's really amazing, these tests that are on the market now and maybe not as widespread as we'd like, but there's a lot of nice assays out there that will become more popular and used more commonplace in the future that I think are going to help identify myeloma more precisely. ... If you think about myeloma, even with measurable residual disease (MRD), MRD for leukemia, for lymphoma, you take a blood sample, you test it for MRD. For myeloma, you need a bone marrow biopsy. You need a bone marrow sample. You can't do MRD on a blood sample for myeloma. Not yet. But if we perfect these assays and we can eventually detect this, then you're looking at a whole new ballgame. You can even perfect your MRD testing as well. So, it's a very exciting time for some of these heme malignancies." TS 28:09

In today's episode, we continue our myeloma series, this time we'll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!Content:- Defining MGUS- Discussing risk of progression of MGUS to MM- How to interpret free light chains in renal failure- How do we monitor MGUS patients?- When do we do additional testing in MGUS?- What is smoldering myeloma?- What are myeloma defining events?- How do we risk stratify SM patients?- How do we monitor SM patients? Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co ** Want to review the show notes for this episode and others? Check out our website: Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

It's been 3 years since our last myeloma series updates and the reality is, a lot has changed! Instead of releasing an updates episode, we are redoing our prior myeloma series to make sure that you, our listeners, can follow along the way you always have. In the first episode in our highly-anticipated multiple myeloma series, we begin our discussion about introduction to testing/workup for plasma cell dyscrasias and having our initial discussion about monoclonal gammopathy of undetermined significance (MGUS). Contents:- What is a plasma cell ?- What is a plasma cell dyscrasia?- What is an "SPEP"?-What is "immunofixation"?-What are "serum free light chains"?-Checking UPEP-Does everyone need a bone marrow biopsy and/or additional workup?-What is MGUS?** Want to review the show notes for this episode and others? Check out our website: Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Episode Info Jim has over thirty years of experience in the insurance and insurtech industries, with a proven track record of success in leading and growing companies. In Jim's previous role as CEO of bolt Solutions Inc, he grew the company's revenue and oversaw the transformation of its business model, enabling the company to grow and scale quickly and efficiently. He has extensive experience creating unparalleled business success in the insurance and insurtech space, administering pragmatic and analytical decisions in high-pressure environments. His enthusiasm for embracing cutting-edge technologies and fostering a culture of innovation aligns perfectly with MISSON's transformative and forward-thinking core values. Episode Overview: In this engaging episode of The Future of Insurance, we sit down with Jim Dwane, CEO of Mission, recorded live at ITC Vegas 2025. Jim shares his insights on the evolving landscape of the insurance industry and how Mission is at the forefront of this transformation. Key Discussion Points: Jim Dwane's Background: Jim discusses his extensive career in the insurance industry, having spent two-thirds of it with major carriers like Travelers and AIG before venturing into the insuretech space in 2017. Mission's Role and Vision: Mission is described as a program administrator that builds de novo programs, focusing on finding exceptional underwriters and providing them with the opportunity to become entrepreneurs. The company acts as an incubator and accelerator for MGUs (Managing General Underwriters), emphasizing a technology-first approach. Strategic Advisory and Support: Mission provides strategic advisory services, helping underwriters manage aspects beyond underwriting, such as capital management, marketing, and compliance. The company supports its partners with administrative, operational, and technological infrastructure. Industry Trends and Future Outlook: Jim highlights the rapid growth of the program space within the insurance industry and the importance of speed and innovation. The discussion touches on the strategic use of technology to accelerate industry transformation. Mission's Partnerships: Mission collaborates with multiple capacity partners, including its parent company, Accelerant, to ensure a robust support system for its MGUs. Conclusion: Join us for this insightful conversation with Jim Dwane as we explore the future of insurance and how Mission is paving the way for innovation and growth in the industry. Whether you're an industry veteran or new to the field, this episode offers valuable perspectives on the dynamic changes shaping the insurance landscape.   This episode is brought to you by The Future of Insurance book series (future-of-insurance.com) from Bryan Falchuk. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

In episode 288 of FNO: InsureTech, Cameron MacArthur, Founder and CEO of AI Insurance, returns to share how his company, operating for over seven years, has navigated dramatic changes in insurance through the practical application of artificial intelligence. Drawing on experiences since Y Combinator in 2019, Cameron discusses the platform's growth to more than 100 specialty and commercial insurance programs, and offers specific examples where AI replaces manual tasks, such as data extraction and invoice processing. The conversation also addresses the shifting insurance landscape, evolving customer expectations, and the leadership challenges of adopting automation while retaining vital insurance expertise. Key Highlights AI Insurance recorded 150% growth in the past year, now supporting more than 100 programs for MGAs, MGUs, captives, and risk retention groups. Cameron describes AI's effectiveness in automating loss-run data import, handling invoices, and migrating complex data—with internal tests and client experiences indicating accuracy and time savings compared to manual processes. The rise of MGAs and MGUs is reshaping the market, with premium volume in this sector doubling since 2020, while traditional carriers and captives remain static or decline. Modern SaaS and AI solutions have reduced the barriers and costs of launching insurance programs, enabling new entities to go live in weeks rather than months. Cameron details a significant change in client expectations: prospects increasingly seek direct access to AI, APIs, and custom tooling, reflecting greater technical familiarity within insurance operations. Leadership must recognize and address staff concerns as automation alters job scopes, emphasizing the need for communication, retraining, and a continued focus on deep insurance knowledge. Cameron shares personal perspectives on the ongoing complexity of insurance, the rewards of continued learning, and the realities of leading sustainable growth.  Special Offer: Use our coupon code  ITCFNO200 to get $200 OFF your ITC Vegas pass! See you in Vegas! 

This episode of In The Know features host Chris Hampshire and Leah Ohodnicki, Executive Vice President of Carrier Relations at RT Specialty. Leah leads strategic initiatives to strengthen trading partnerships and drive growth across the wholesale insurance landscape, and brings two decades of experience spanning retail brokerage, E&S carriers, MGUs, and program business. Leah began her career at Marsh in 2006, advancing through leadership roles in marketing and business development. In 2015, she joined Argo Group, where she led distribution for the group and later led Specialty Programs. Leah also served as the executive sponsor for Argo Group's Gender Equality employee resource group. In 2023, Leah joined Ethos Specialty, part of Ascot Group, where she led Strategic Partnerships and served as interim head of Casualty Programs. Leah co-chairs the community committee for RT Specialty's WOW! — Women Opportunity Winning! — and serves on the boards of the Pittsburgh CLO and the University of Pittsburgh's Frederick Honors College. Today, Leah and Chris discuss the wholesale specialty marketplace, the role of distribution, and other aspects of this industry segment, and Leah's experience as a female leader in the insurance industry.   Key Takeaways Leah's career journey from marketing to insurance. Roles and responsibilities of leading carrier relations. The current state of the wholesale specialty sector. Key differences between wholesale and primary markets. Leah's message to anyone considering a career in insurance. Leah's experience as a female leader in insurance. Technical capabilities and character considerations in the hiring process. The value of a CPCU designation in an insurance career. Questions Leah asked herself when considering career moves. Technology's impact on the wholesale sector. A five-year look at the future of the industry. Leah's advice to her college-aged self.   In the Know podcast theme music written and performed by James Jones, CPCU, and Kole Shuda of the band If-Then.   To learn more about the CPCU Society, its membership, and educational offerings, tools, and programs, please visit CPCUSociety.org.   Follow the CPCU Society on social media: X (Twitter): @CPCUSociety Facebook: @CPCUSociety LinkedIn: @The Institutes CPCU Society Instagram: @the_cpcu_society   Quotes “Carriers are all looking for ways to access brokers that they want to do business with.” “The wholesale specialty sector is in a really healthy place right now.” “Within insurance, you have the ability to be exposed to so much about what is going on in the world.” “Insurance is at the heart of the economy.” “If you have a seat at the table, you're there for a reason. Own it!” “What is the brand that you're building on your social media platform?”  

Angioedema – Recognition and Management in the ED Hosts: Maria Mulligan-Buckmiller, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Angioedema.mp3 Download Leave a Comment Tags: Airway Show Notes Definition & Pathophysiology Angioedema = localized swelling of mucous membranes and subcutaneous tissues due to increased vascular permeability. Triggers increased vascular permeability → fluid shifts into tissues. Etiologies Histamine-mediated (anaphylaxis) Associated with urticaria/hives, pruritus, and redness. Triggered by allergens (foods, insect stings, medications). Rapid onset (minutes to hours). Bradykinin-mediated Hereditary angioedema (HAE): C1 esterase inhibitor deficiency (autosomal dominant). Acquired angioedema: Associated with B-cell lymphoma, autoimmune disease, MGUS. Medication-induced: Most commonly ACE inhibitors; rarely ARBs. Typically lacks urticaria and itching. Gradual onset, can last days if untreated. Idiopathic angioedema Unknown cause; diagnosis of exclusion. Clinical Presentations Swelling Asymmetric, non-pitting, usually non-painful. May involve lips, tongue, face, extremities, GI tract. Respiratory compromise Upper airway swelling → stridor, dyspnea, sensation of throat closure. Airway obstruction is the most feared complication. Abdominal manifestations

What does it take to fundamentally rethink how specialty insurance is traded, structured and scaled? In this episode, Robin Merttens is joined by Jeff Radke, co-founder and CEO of Accelerant, for a deep dive into the mechanics of a rapidly growing risk exchange that's quietly reshaping the MGA and MGU landscape. It has been three years since Jeff joined us on the InsTech podcast, and even Accelerant has radically evolved as a business. This isn't, however, just another technology story. Jeff shares frank insights on building trust in a data-driven ecosystem, how Accelerant has used AI to make tangible portfolio improvements and why he believes platform-based risk trading will become the dominant model for specialty lines. Unlike many other discussions about AI in insurance, this episode focuses on what's already working – from subrogation improvements to portfolio optimisation. There's also a broader message here: about stepping back to see how much the market has changed and why the next evolution may already be underway… Key Talking Points Building a global risk exchange – how Accelerant connects specialty MGAs and MGUs with capacity through a single, scalable platform The value of long-term partnerships – why Accelerant provides five-year capacity commitments and expects transparency in return From niche to global – supporting 200+ underwriting teams across 20 countries and over 225 specialty products Applying AI where it matters – reducing loss ratios and boosting subrogation with machine learning and large language models Cost leadership in a softening market – why expense ratio advantage trumps rate cycles in SME and specialty risks Looking ahead – how AI is reshaping roles, workflows and the entire insurance value chain The rise of risk exchanges – why specialty insurance is following the same path as bonds, mortgages and equities Staying ahead – why Accelerant is focused on evolution, not just competition If you like what you're hearing, please leave us a review on whichever platform you use or contact Robin Merttens on LinkedIn. You can also contact Jeff Radke on LinkedIn to start a conversation! Sign up to the InsTech newsletter for a fresh view on the world every Wednesday morning. Continuing Professional Development This InsTech Podcast Episode is accredited by the Chartered Insurance Institute (CII). By listening, you can claim up to 0.5 hours towards your CPD scheme. By the end of this podcast, you should be able to meet the following Learning Objectives: Describe how a modern risk exchange connects specialty underwriters with capital providers. Identify the signs of systemic evolution in the insurance industry that indicate a shift toward platform-based models. Define the concept of a two-sided risk exchange and its advantages over traditional capacity models. If your organisation is a member of InsTech and you would like to receive a quarterly summary of the CPD hours you have earned, visit the Episode 348 page of the InsTech website or email cpd@instech.co to let us know you have listened to this podcast. To help us measure the impact of the learning, we would be grateful if you would take a minute to complete a quick feedback survey.

On this episode Lara and Vyanka talk to Prof Guy Pratt from The University of Birmingham all about the diagnosis of, management of and advances in plasma cell disorders like MGUS and multiple myeloma. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

Episode 184: Multiple Myeloma BasicsSub-Interns and future Drs. Di Tran and Jessica Avila explain the symptoms, work up and treatment of multiple myeloma. Written by Di Tran, MSIV, Ross University School of Medicine; Xiyuan Yang, MSIV, American University of the Caribbean. Comments by Jessica Avila, MSIV, American University of the Caribbean. Edits by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Di: Hi everyone, this is Di Tran, 4th year medical student from Ross university.  It's a pleasure to be back.  To be honest, this project is a part of teamwork of two medical students, myself and another 4th year, her name is XiYuan.  She came from the AUC. Unfortunately, due to personal matters she was unable to make it to the recording today which makes me feel really sad. Jessica: My name is Jessica Avila, MSIV, American University of the Caribbean.Di: The topic we will present today is Multiple Myeloma. Multiple myeloma is typically a rare disease and it's actually a type of blood cancer that affects plasma cells in the bone marrow.Jessica: Let's start with a case: A 66-year-old male comes to his family doctor for an annual health checkup. He is not in any acute distress but he reports that he has been feeling tired and weaker than usual for the last 3 months. He also noticed that he tends to bruise easily. He has a history of arthritis and chronic joint pain, but he thinks his back pain has gotten worse in the last couple of months. Upon checking his lab values, his family doctor found that he has a calcium level of 10.8 and a creatinine level of 1.2, which has increased from his baseline. Given all that information, what do you think his family doctor is suspecting? And what kind of tests she can order for further evaluation?Di: Those symptoms sound awfully familiar – are we talking about the CRAB? You know, the diagnostic criteria for Multiple Myeloma.Jessica: Exactly! Those are called “myeloma-defining events.” Do you remember what those are?Di: CRAB criteria comes in 4 flavors.  It's HYPERCALCEMIA with >1mg/dL, RENAL INSUFFICIENCY with serum creatinine >2mg/dL, ANEMIA with hemoglobin value 10% plasma cells, PLUS any one or more of the CRAB features, we can make the official diagnosis of multiple myeloma. Di:  Before we go deeper, let's back up a little bit and do a little background.  So, what do we know about the immunoglobulins, also known as antibodies? Back from years of studying from medical school, we know that the plasma cells are the ones that producing the antibodies that help fight infections.  There  are various kinds that come with various functions.  Each antibody is made up of 2 heavy chains and 2 light chains.  For heavy chains, we have A, D, E, G, M and for light chains we have Kappa and Lambda.Jessica: Usually, the 5 possible types of immunoglobulins for heavy chains would be written as IgG, IgA, IgD, IgE, and IgM.  And the most common type in the bloodstream is nonetheless the IgG. Di: What is multiple myeloma? In myeloma, all the abnormal plasma cells make the same type of antibody, the monoclonal antibody.  The cause of myeloma is unknown, but there are lots of studies and evidence that show a number of potential etiologies, including viral, genetic, and exposure to toxic chemicals, especially the Agent Orange, which is a chemical used as herbicide and defoliant. It was used as a chemical warfare by the U.S. military during the Vietnam War from 1961 to 1971.Jessica: We need to order some specific blood tests to see if there is elevated monoclonal proteins in the blood or urine. So, to begin with we'll need to take a very thorough history and physical exam. Next, we'll do labs, such as CBC, basic metabolic panel, calcium, serum beta-2 microglobulin, LDH, total protein, and some not so common tests: serum protein electrophoresis (SPEP), immunofixation of blood or urine (IFE), quantitative immunoglobulins (QIg), serum free light chain assay, and serum heavy/light chain ratio assay.If any of the results is abnormal, we should consider referring our patient to an oncologist.Di: Interesting! I read that Multiple Myeloma symptoms vary in different patients.  In fact, about 10-20% of patients with newly diagnosed myeloma do not have any symptoms at all.   Otherwise, classic symptomatic presentations are weakness, fatigue, increased bruising under the skin, reduced urine output, weakened bones that is likely prone to fractures, etc. And if multiple myeloma is highly suspected, a Bone Marrow biopsy should be done with testing for flow cytometry and fluorescent in situ hybridization (FISH). Actually, if any of the “Biomarkers of malignancy (SLIM)” is met we can also diagnose multiple myeloma even without the CRAB criteria. Jessica: The diagnosis is made if one or more of the following is found: >= 60% of clonal plasma cells on bone marrow biopsy, > 1 lytic bone lesion on MRI that is at least 5mm in size, or a biopsy confirmed plasmacytoma. Di: Imaging comes in at the final step especially if we able to find one or more sites of osteolytic bone destruction > 5mm on an MRI scan.Jessica: What if the bone marrow biopsy returns > 10% of monoclonal plasma cells, but our patient doesn't have either the CRAB or the Biomarker criteria? Di: That's actually a very good question, since Multiple Myeloma is part of a spectrum of plasma cell disorders. That's when smoldering myeloma comes into play. It is a precursor of active multiple myeloma. Smoldering myeloma is further categorized as high-risk or low-risk based on specific criteria.A less severe form is called Monoclonal Gammopathy of Undetermined Significance, or simply MGUS, with < 10% bone marrow involvement. Those are diagnoses we give once we rule out actual multiple myeloma, which are defined by the amount of M-protein in the serum.Jessica:  When to get started on treatment? Multiple Myeloma is on a spectrum of plasma cells proliferative disorders, starting from MGUS to Smoldering Myeloma, to Multiple Myeloma and to  Plasma Cell Leukemia.  Close supervision/active watching is enough for MGUS and low risk Smoldering Myeloma. But once it has progressed to high-risk smoldering myeloma or to active Multiple Myeloma, chemotherapy is usually required. Some situations may require emergent treatment to improve renal function, reduce hypercalcemia, and to prevent potential infections.Di: As of 2024, treatment of Multiple Myeloma comprises the Standard-of-Care approved by the FDA. In fact, the quadruple therapy is a combination of 4 different class of drugs that include a monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug, and a steroid. Jessica: They are Darzalex (daratumumab), Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone.  Other treatment plans for Multiple Myeloma include chemotherapy, immunotherapy, radiation therapy (for plasmacytomas) and stem cell transplants. The patient will also be on prophylaxis acyclovir and Bactrim while on chemotherapy. Sometimes anticoagulants are also considered because the chemo increases the risk of venous thromboembolic events.Di: Although the disease is incurable, but with the advancing of novel therapies and clinical trials patients with multiple myeloma are able to live longer.  Problem is the majority of patients diagnosed with Multiple Myeloma are older adults (>65), the risk of falling is adding to multiple complications of the disease itself, such as bone density loss, pain, neurological compromises, distress and weakness.  Palliative care may come in help at any point in time throughout the course of treatment but is most often needed at the very end of the course. Jessica, can you give us a conclusion for this episode?Jessica: Multiple Myeloma may not be the most common cancer, but we have to be aware of the symptoms and keep it in our differential diagnosis for patients with bone pain, easy bruising, persistent severe headaches, unexplained renal dysfunction, and remember the CRAB: HyperCalcemia, Renal impairment, Anemia and Bone lesions.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:International Myeloma Foundation. (n.d.). International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. https://www.myeloma.org/international-myeloma-working-group-imwg-criteria-diagnosis-multiple-myeloma Laubach, J. P. (2024, August 28). Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics). UpToDate. https://www.uptodate.com/contents/multiple-myeloma-symptoms-diagnosis-and-staging-beyond-the-basics.University of California San Francisco. (n.d.). About multiple myeloma. UCSF Helen Diller Family Comprehensive Cancer Center. https://cancer.ucsf.edu/research/multiple-myeloma/about Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Dawn Walker is an associate director, Industry Relations (DUAE) in AM Best's Strategy and Communications department. Dawn has more than 15 years of insurance industry and risk management experience, and joined AM Best in 2022, initially serving as a senior financial analyst, conducting performance assessments for Delegated Underwriting Authority Enterprises.  Previously, Dawn as a senior risk management analyst at MacAndrews & Forbes Inc., a global mergers and acquisitions firm in New York City. She also previously served as a senior account executive for Alliant Insurance Services, serving its ultra-high net worth book of business.  Dawn received her MBA degree with a concentration in Enterprise Risk Management at St. John's University. She graduated Cum Laude earning a Bachelor of Law degree from the University of Arizona. She holds a Property & Casualty and Life & Health Broker's license, has earned an Associate in Risk management (ARM) designation and is actively pursuing a Charter Property Casualty Underwriter's designation. Highlights from the Show AM Best is known for many things, but mainly for the assessments and ratings they perform on players across the insurance industry. For the Delegated Underwriting Authority Enterprise (DUAE) space in particular, they are bringing transparency to help drive continued growth not only of the DUAE segment, but the product innovation that goes on within it. The level of growth in the delegated underwriting authority space has been huge, getting to $77B in the US alone, and making up 10% of the P&C market globally. The key areas they look at when assessing DUAEs includes Operations, UW Capabilities, Governance and Controls, Financials and Corporate Structure. This analysis helps bring transparency to the sector to help facilitate partnerships while also giving DUAEs a blueprint for how to optimize their operations for growth, stability and, ultimately, success Why do insurers work with Delegated Underwriting Authority Enterprises (DUAEs), like MGAs and MGUs? Can't they just compete in the market directly? DUAEs bring expertise in niches and market segments that incumbent carriers may not be able to build efficiently given their scale, and the relative size of these niches being too small to support the operational cost of a carrier. DUAEs often come with expertise and distribution in the segment, allowing carriers working with them to access new spaces efficiently, quickly and profitably. What can support or stand in the way of the success of a Delegated Underwriting Authority Enterprises (DUAEs), like MGAs and MGUs? AM Best performs assessments of these entities to bring transparency to key success factors insurers would look at when deciding whether to work with a DUAE or not. This episode is brought to you by The Future of Insurance thought leadership series, available globally from Amazon in print, Kindle and Audible audiobook. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.

Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr. Elizabeth O'Donnell, Director of Early Detection and Prevention at Dana-Farber.

Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr. Elizabeth O'Donnell, Director of Early Detection and Prevention at Dana-Farber.

In episode 12, we're joined by haematology consultant Dr Suzanne Roberts to discuss myeloma. Dr Roberts explains what kind of pain to look out for – like back pain – in this type of blood cancer and how to tell the difference between a musculoskeletal pain versus a pain without a mechanism of injury, or a new-onset pain. She talks through other symptoms like fatigue and anaemia, the C.R.A.B acronym, MGUS, staging ,and the primary care investigations she would recommend. You can access the guidelines and studies referenced here. Accessibility: Access the full episode transcript here. If you loved this episode and would like to hear more like this, please leave a review, a rating and share the episode. GPs Talk Cancer is the podcast series from GatewayC. GatewayC is the free early cancer diagnosis resource funded by the NHS and is part of The Christie NHS Foundation Trust. Produced by Louise Harbord from GatewayC, and Jo Newsholme from Rethink Audio.DISCLAIMER: We know this podcast might be of interest to anybody, however it is aimed at primary care health professionals. All patient cases are based on real stories from our clinical practice as GPs. They are fully anonymised with no identifiable patient data. All featured statistics are accurate at the time of recording. All views expressed by guest speakers are their own. Hosted on Acast. See acast.com/privacy for more information.

Tony chats with Jeff Radke, Co-Founder and CEO at Accelerant Holdings. Accelerant has been around for 5 years and exists to improve the specialty insurance value chain. They are "replatforming" the specialty insurance market. They serve specialty underwriters (MGAs and MGUs) and on the other side they serve risk capital sources. Their vision is an incredibly efficient infrastructure that reduces friction as much as possible.Jeff Radke: https://www.linkedin.com/in/jeff-radke/Accelerant: https://accelerant.ai/Video Version: https://youtu.be/OT_Lzaq1tIgWhat It's Like To Be...What's it like to be a Cattle Rancher? FBI Special Agent? Professional Santa? Find out!Listen on: Apple Podcasts Spotify

Tune into this week's epsiode of of The Leadrship In Insurance Podcast : A Deep Dive Into MGUs, Digital Underwriting & MGA Opportunites with Caroline Taylor ACII, COO at ACIES MGU➡ Why do we need another MGU platform?➡ What do you mean when you say digital underwriting? Is this not just how underwriting is done?➡ You have some pledges around social and environmental issues - what are you doing practically?➡ Acies has significant growth ambitions over the next few years to support a growing number of MGAs - its a competitive landscape how do you secure the best MGA opportunities? Hosted on Acast. See acast.com/privacy for more information.

Is there anything you can suggest to people with MGUS to proactively keep multiple myeloma at bay?; Would you please comment on the recent study that showed no benefits to time-restricted eating?; Our 12-year-old grandson has Sever's disease. Any supplements you would recommend for him?

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Monoclonal Gammopathy of Undetermined Significance (MGUS)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the... The post Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification appeared first on VJHemOnc.

Unlock the secrets behind the burgeoning InsurTech industry with David Gritz, the co-founder and managing director of InsurTechNY. ✅ Join over 5,000 newsletter subscribers: https://go.ryanhanley.com/** ✅ For daily insights and ideas on peak performance: https://www.linkedin.com/in/ryanhanley** ✅ Subscribe to the YouTube show: https://youtube.com/ryanmhanley Connect with David on LinkedIn: https://www.linkedin.com/in/davidgritz/ Our enlightening conversation peels back the layers of how MGAs and MGUs are revolutionizing insurance, offering targeted risk solutions and reshaping the industry for independent agents and consumers alike. Hear firsthand about the incubator-like MGA lab where innovation thrives, and the transformative impact these entities have on both commercial and personal insurance realms. Navigating the tech sphere's entrepreneurial waters can be a tumultuous journey, one that often serves up equal parts laughter and frustration. We swap stories of customer service mishaps that remind us of the importance of accessibility and efficiency—key ingredients to a successful InsurTech venture. The dialogue veers into the potential of artificial intelligence and the seamless integration that entices even investors to become customers, as exemplified by the ease of policy purchases with companies like Chase.  The insurance world is a complex tapestry, but this episode cuts through the intricacy with precision, revealing how aspiring MGA businesses can scale and prosper. From the nitty-gritty of actuarial strategies to the tactical maneuvers of geographic expansion, the keys to a thriving MGA enterprise are laid bare. And for those eager to dip their toes into the InsureTech revolution, we extend a warm invitation to join the vibrant community at InsurTechNY, your launchpad for networking and innovation in the heart of New York. Learn more about your ad choices. Visit megaphone.fm/adchoices

Unlock the secrets behind the burgeoning InsurTech industry with David Gritz, the co-founder and managing director of InsurTechNY.✅ Join over 5,000 newsletter subscribers: https://go.ryanhanley.com/**✅ For daily insights and ideas on peak performance: https://www.linkedin.com/in/ryanhanley**✅ Subscribe to the YouTube show: https://youtube.com/ryanmhanleyConnect with David on LinkedIn: https://www.linkedin.com/in/davidgritz/Our enlightening conversation peels back the layers of how MGAs and MGUs are revolutionizing insurance, offering targeted risk solutions and reshaping the industry for independent agents and consumers alike.Hear firsthand about the incubator-like MGA lab where innovation thrives, and the transformative impact these entities have on both commercial and personal insurance realms.Navigating the tech sphere's entrepreneurial waters can be a tumultuous journey, one that often serves up equal parts laughter and frustration. We swap stories of customer service mishaps that remind us of the importance of accessibility and efficiency—key ingredients to a successful InsurTech venture.The dialogue veers into the potential of artificial intelligence and the seamless integration that entices even investors to become customers, as exemplified by the ease of policy purchases with companies like Chase. The insurance world is a complex tapestry, but this episode cuts through the intricacy with precision, revealing how aspiring MGA businesses can scale and prosper. From the nitty-gritty of actuarial strategies to the tactical maneuvers of geographic expansion, the keys to a thriving MGA enterprise are laid bare.And for those eager to dip their toes into the InsureTech revolution, we extend a warm invitation to join the vibrant community at InsurTechNY, your launchpad for networking and innovation in the heart of New York.Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions:    Bri: Hello, I have a friend who was recently diagnosed with MGUS (monoclonal gammopathy) a condition in which an atypical protein is found in the blood and you have a increased risk of having cancer in the future. If this were you, what would you do? Or what path would you start looking down?   Alicia: A holistic chiropractor informed us that our 6 year old son has a hiatal hernia. His symptom is a cough at night after he's been asleep about an hour that eventually progresses to him throwing up. After that he's able to return to sleep. This used to happen a few times a year and now it's just been once so far this winter. Please explain what a hiatal hernia is, if it's common in children, and how we can help him.   HC: Hello Dr. Cabral, Thank you for all you do for your community. I appreciate your selflessness and committment to inform us on real truths of healing!! Do you any knowledge on antioxidant Carbon 60? I have been looking at product (Carbon360) and would appreaciate your feedback. THank you again for all you do!!!!   Heather: Hey doc! Thanks as always for taking the time to answer our questions. Could you talk more in-depth about Beau's lines (the horizontal dents in nails that make them look warp-liked)? I listened to your podcasts on nails and you briefly mentioned these lines mean digestive-based issues. I've gone through the CBO Protocol & Gut Finisher, did a Food Sensitivity test & confirmed I only have a moderate sensitivity to rye & miso. The Beau's lines weren't something I noticed until recently when they started appearing on my fingernails but now I realize I've had them on my toenails for quite some time, otherwise, I would have brought it up to my health coach at the time I was working through the CBO. Thanks again!   Sienna: Hi doctor Cabral, I (47F) would love to do a 3-day water fast for health benefits, but without messing up my hormones and losing muscle. What would be the best way to approach this? Thanks so much for your answer! Sienna   Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/2955 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

A look at Multiple Myeloma (including MGUS), covering pathophysiology as well as signs and symptoms of multiple myeloma (CRAB criteria). Also includes the diagnostic criteria and treatment.Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Multiple Myeloma?0:21 Multiple Myeloma Pathophysiology 1:34 Plasma Cell Dyscrasias2:57 Multiple Myeloma Symptoms5:59 Multiple Myeloma Causes & Risk Factors6:51 Multiple Myeloma Diagnosis7:11 Multiple Myeloma Diagnostic Criteria7:38 Multiple Myeloma TreatmentReferencesJames R. Berenson - **MSD Manual Pro (2023) Multiple Myeloma. Available at https://www.msdmanuals.com/professional/hematology-and-oncology/plasma-cell-disorders/multiple-myelomaSara A. Albagoush; Cameron Shumway; Alexandre M. Azevedo (2023) Multiple Myeloma. Available at https://www.ncbi.nlm.nih.gov/books/NBK534764International Myeloma Foundation (2021) What Are MGUS, Smoldering Multiple Myeloma, and Active Myeloma? Available at https://www.myeloma.org/what-are-mgus-smm-mmS. Vincent Rajkumar (2022) Smoldering multiple myeloma current treatment algorithms. Available at https://www.nature.com/articles/s41408-022-00719-0/Sumana Kundu (2022) Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management. Available at https://www.cureus.com/articles/86261-multiple-myeloma-and-renal-failure-mechanisms-diagnosis-and-management#!/Please remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. 

When discussing Osteoporosis treatment, your physician will most likely prescribe some medications. With the different drugs out there, how do you know which one to take? Is it safe if you have other medical conditions? What are the long-term side effects? Which is a better brand? And the list goes on.   Today, I have someone who will answer your questions about Osteoporosis medications to put your mind at ease.   Dr. R. Keith McCormick is a chiropractic physician specializing in the management of patients with osteoporosis. He is the author of the recently released book Great Bones: Taking Control of Your Osteoporosis and The Whole Body Approach to Osteoporosis.    Sports have always played a vital part in Dr. McCormick's life. He is the former U.S. record holder for the most points scored in a pentathlon competition. Dr. McCormick continues to compete in triathlons of all distances and has completed six Ironman competitions, five of them after recovering from multiple osteoporosis-related fractures.   So, if you have questions about Osteoporosis medications, listen to this informative episode of the Happy Bones, Happy Life podcast!    “I always talk about medications as being a short-term solution to a long-term issue. And that is, when you're taking the medications, all that time you're (also) doing things to improve your overall bone health—your diet and supplements, all that.” - Dr. R. Keith McCormick   In this episode: - [02:10] - How long can you stay on Prolia? - [05:31] - How can I prevent the rebound effect from quitting Prolia? - [10:47] - Should I continue using Prolia?  - [12:08] - How long do most people use Prolia? - [13:56] - How to achieve long-term success in your battle with Osteoporosis  - [17:52] - What can I do to prevent the adverse effects of taking teriparatide? - [19:55] - Forteo vs. Tymlos - [21:59] - What are the effects of MGUS, and is there anything we can do about it? - [24:43] - Can I safely quit taking Prolia with my current medical condition? - [26:57] - Will mast cell activation affect your bone health? - [27:36] - I have Osteoporosis and breast cancer. My oncologist prescribed Raloxifene. I'm not sure about taking it. Who do I see for testing and the meds? - [33:42] - I used to take Forteo, then stopped. If I use it again, will it have the same effect as building bone density the first year? - [37:32] - It's important to do these things before taking tests and medications - [42:21] - I'm 74 and have scoliosis. My doctor has recommended I take either Forteo or Prolia. Which drug should I take? - [44:15] - How important is Vitamin K2 to your bone health?   Resources mentioned - The Happy Bones Club - https://www.happyboneshappylife.com/bones-club - Great Bones: Taking Control of Your Osteoporosis - R. Keith McCormick, DC - https://www.osteonaturals.com/product-page/great-bones-taking-control-of-your-osteoporosis - Consult with Dr. McCormick - https://www.osteonaturals.com/consult-osteonaturals   More about Margie - Website - https://margiebissinger.com/  - Facebook - https://www.facebook.com/p/Margie-Bissinger-MS-PT-CHC-100063542905332/  - Instagram - https://www.instagram.com/margiebissinger/?hl=en    DISCLAIMER – The information presented on this podcast should not be construed as medical advice. It is not intended to replace consultation with your physician or healthcare provider. The ideas shared on this podcast are the expressed opinions of the guests and do not always reflect those of Margie Bissinger and Happy Bones, Happy Life Podcast. *In compliance with the FTC guidelines, please assume the following about links on this site: Some of the links going to products are affiliate links of which I receive a small commission from sales of certain items, but the price is the same for you (sometimes, I even get to share a unique discount with you). If I post an affiliate link to a product, it is something that I personally use, support, and would recommend. I personally vet each and every product. My first priority is providing valuable information and resources to help you create positive changes in your health and bring more happiness into your life. I will only ever link to products or resources (affiliate or otherwise) that fit within this purpose.  

BUFFALO, NY- January 22, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.” Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in the bone marrow. In spite of recent advances in the field of MM, the disease has remained incurable. MM is preceded by a premalignant state known as monoclonal gammopathy of undetermined significance (MGUS), with a risk of progression to MM of 1% per year. Establishing a scalable approach that refines the identification of MGUS patients at high risk of progression to MM can transform the clinical management of the disease, improve the patient's quality of life, and will have significant socioeconomic implications. In this new perspective, researchers Bilal M. El-Masri, Benedeta Leka, Fatima Mustapha, Michael Tveden Gundesen, Maja Hinge, Thomas Lund, Thomas L. Andersen, Marta Diaz-delCastillo, and Abbas Jafari from the Danish Spatial Imaging Consortium, University of Southern Denmark, University of Copenhagen, University of Aarhus, Odense University Hospital, and Lillebaelt Hospital provide evidence that changes in the bone marrow adipose tissue (BMAT) provide an early sign for progression from MGUS to MM. “We employed AI-assisted histological analysis of unstained bone marrow biopsies from MGUS subjects with or without progression to MM within 10 years (n = 24, n = 17 respectively).” Although the BMAT fraction was not different between the two groups, bone marrow adipocyte (BMAd) density was decreased in MGUS patients who developed MM, compared to non-progressing MGUS patients. Importantly, the distribution profile for BMAd size and roundness was significantly different between the two groups, indicating a shift toward increased BMAd size and roundness in MGUS patients who developed MM. These early changes in the BMAT could serve as valuable early indicators for the transition from MGUS to MM, potentially enabling timely interventions and personalized treatment strategies. “[...] the AI-based approach for histological characterization of unstained bone marrow biopsies is cost-effective and fast, rendering its clinical implementation feasible.” DOI - https://doi.org/10.18632/oncotarget.28548 Correspondence to - Abbas Jafari - ajafari@sund.ku.dk, Marta Diaz-delCastillo - marta@forens.au.dk, and Thomas L. Andersen - thomas.levin.andersen@rsyd.dk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28548 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, multiple myeloma, MGUS, bone marrow adipocyte About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1.      New diagnostic criteria for light chain MGUS (IStopMM):              https://ash.confex.com/ash/2023/webprogram/Paper188547.html             https://ash.confex.com/ash/2023/webprogram/Paper182661.html2.     PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma: https://ash.confex.com/ash/2023/webprogram/Paper191911.html 3.     ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma: https://ash.confex.com/ash/2023/webprogram/Paper177546.html 4.     Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma: https://ash.confex.com/ash/2023/webprogram/Paper180766.html 5.     GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma) https://ash.confex.com/ash/2023/webprogram/Paper178835.html 6.     Overall survival results of KarMMa-3 trial https://ash.confex.com/ash/2023/webprogram/Paper178933.html 7.      GEM2017FIT Trial: Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients: https://ash.confex.com/ash/2023/webprogram/Paper179866.html      

Discussing how to treat MGUS (Monoclonal gammopathy of undetermined significance) and Smoldering Myeloma using an algorithm with Dr. S. Vincent Rajkumar. We covered MGUS and smoldering myeloma in great detail, following with how these patients should be monitored and if any of these patients should be treated. Dr. S. Vincent Rajkumar is a world-renowned physician who specializes in plasma cell disorders - Professor of Medicine at the Mayo Clinic Comprehensive Cancer Center.

Jeff Radke is CEO and Co-Founder of Accelerant, a technology-fueled insurance platform that empowers MGUs to more effectively and confidently serve small and medium enterprises. He has spent his career working across all areas of the insurance value chain, from underwriting to reinsurance in global markets. Prior to Accelerant, Jeff spent a decade at Argo Group International Holdings, but he became frustrated with thelegacy system's antiquated technology and emphasis on maintaining their position in the value chain over doing right by the customer. This inspired him to co-found Accelerant to enable data-driven innovation and collaboration that puts customers first. Accelerant rebuilds the way that underwriters share and exchange risk to improve outcomes for everyone, with a focus on the SMBs that power our global economy and their niche insurance needs. Highlights from the Show Jeff started his career in Reinsurance, which gave him an interesting perspective on insurance having looked at it from the end of the value chain Accelerant runs a risk exchange, meaning they connect MGAs/MGUs/Program Administrators (who they call Members) with risk capital on the other side of the platform that likes the kinds of Specialty risks these members are writing In between those parties, Accelerant's platform tries to make the regulatory and system complications as uncomplicated as possible by solving for them for their members It's almost the opposite of what a fronting carrier is, and is more of a portfolio manager of risk They try to provide stability of capital and appetite and the ability to capitalize on every opportunity an MGA finds They've also become a way for existing insurers to get into the E&S or Specialty space without having to build the technology stack, distribution relationships or underwriting talent It's very hard to build a business that can write large, esoteric, specialty risks and the higher volume E&O/PL, BOP and GL It's a completely different human skillset and tech capability to keep a tight watch and understanding on how small, Specialty Lines portfolios change over time They do monthly deep dives with their members to see if anything has changed with appetite, underwriting review, etc. to see if there's a potential driver of performance changes so they can react before it's ballooned out of control Traditionally, program administrators haven't gotten the detailed data they need on things like regulatory compliance, loss trends, filings, etc., and Accelerant has worked to be as transparent as possible rather than treating their information as proprietary or something not to share One reason Jeff thinks E&S will stay strong and not just be a fill-in for what can't go Admitted at the moment is because of the need to keep flexing on product and rate at a speed that the regulatory path cannot keep up with, especially with resource constraints there This episode is brought to you by The Future of Insurance Volume III. The Collaborators, part of the Future of Insurance thought leadership series (future-of-insurance.com) from Bryan Falchuk. Follow the podcast at future-of-insurance.com/podcast for more details and other episodes. Music courtesy of Hyperbeat Music, available to stream or download on Spotify, Apple Music, and Amazon Music and more.

Tony chats with Will Ross, Co-Founder and CEO at Federato. Bringing concepts from portfolio optimization and mixing them with AI and Machine Learning, Federato's RiskOps is an underwriting platform for carriers, MGAs and MGUs providing real-time risk selection and portfolio insights to empower underwriters to balance their book of business and make better underwriting decisions.Will Ross: https://www.linkedin.com/in/williamross826/Federato: https://www.federato.ai/Video Version: https://youtu.be/0cY7D_uFO1w

Sandra Mazzoni, DO, a hematologist at Cleveland Clinic Taussig Cancer Institute joins the Cancer Advances podcast to talk about monoclonal gammopathy of undetermined significance, known as MGUS. Listen as Dr. Mazzoni talks about this abnormal protein and explains when we can still effectively treat patients before it hits all the criteria for becoming multiple myeloma.

A new review paper was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Systemic AL amyloidosis: current approach and future direction.” In this review, researchers Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain from SUNY Upstate Medical University, University of Texas MD Anderson Cancer Center, Monmouth Medical Center, University of Balamand, Cleveland Clinic Ohio, UnityPoint Methodist, Houston Methodist Cancer Center, and Cleveland Clinic Florida report the literature on the latest treatment updates of Systemic Light chain (AL) amyloidosis and the ongoing clinical trials highlighting the future treatments. “In this manuscript, we discuss the general approach towards treating patients with amyloidosis and dive into the future perspectives in this multi-systemic disease.” Systemic AL amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. It is a fatal disease and if not diagnosed and treated early can lead to organ failure and potentially death. The renal system along with the cardiovascular system are the most common organs involved, but other organs such as the gut and liver can be involved as well. The initial evaluation of patients requires confirming the diagnosis with tissue biopsy and staining with Congo red followed by confirmatory typing with mass spectrometry of the Congo red positive tissue. Then establishing the extent of the organs involvement by various staging and biomarkers testing. The treatment options and the tolerability of therapy depend on the disease staging, frailty and co-morbidities. The autologous hematopoietic cell transplantation (HCT) after high dose melphalan therapy is an effective strategy which is usually done after initial bortezomib induction therapy. Unfortunately, most systemic AL amyloidosis patients are not candidates for HCT due to frailty, old age, multi-organ involvement, and renal or heart failure at the time of diagnosis. While it is widely accepted that the patients need to be treated until they achieve complete hematologic response, the maintenance therapy after HCT is not well established in AL amyloidosis. “The relationship between AL amyloidosis and MGUS is less clear, but some studies suggest that the risk of developing AL amyloidosis may be increased in patients with MGUS. It is important for patients with these conditions to undergo regular monitoring and evaluation for signs of AL amyloidosis, as early diagnosis and treatment can improve outcomes.” DOI - https://doi.org/10.18632/oncotarget.28415 Correspondence to - Chakra P. Chaulagain - chaulac@ccf.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28415 Keywords - amyloidosis, management About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

This week's episode will be an introduction to plasma cell dyscrasias. We will cover the diagnostic criteria for MGUS and Smoldering Myeloma as well as introduce Multiple Myeloma.

Top claims challenges for MGAs/MGUs and how to overcome them

Lynda A. Bennett and Eric Jesse continue their discussion with Michael Wakefield from CAC Specialty about MGUs and MGAs in the context of reps and warranties insurance. They address how MGU/MGA-negotiated policies can be insured by multiple insurers that share a percentage of the policy limit, plus the role of the MGU or MGA in the claim process, what incentivizes these entities to be effective advocates on behalf of policyholders, and the risks involved for policyholders choosing MGUs or MGAs. Speaker:Lynda A. Bennett, Partner and Chair, Insurance Recovery Eric Jesse, Partner, Insurance Recovery Michael Wakefield, Executive Vice President – Transactional Insurance Practice Leader, CAC Specialty

In today's episode, Lynda Bennett is joined by Eric Jesse, Partner in Lowenstein's Insurance Recovery Group, and Michael Wakefield, Transactional Insurance Practice Leader from CAC Specialty to explore the differences between traditional insurers that issue rep and warranty policies and other types of transactional risk policies, and MGUs and MGAs, otherwise known as managing general underwriter or agents. How do MGUs and MGAs differ from traditional insurers and from each other, and what are the respective benefits of each for different types of claims? Speaker:Lynda A. Bennett, Partner and Chair, Insurance Recovery Eric Jesse, Partner, Insurance Recovery Michael Wakefield, Executive Vice President – Transactional Insurance Practice Leader, CAC Specialty

In this continuation of our myeloma series, we discuss the progression of MGUS & smoldering myeloma to multiple myeloma. We also outline how to risk stratify a patient with multiple myeloma and gauge their response to treatment. Content:-What is the natural progression from MGUS to smoldering myeloma to multiple myeloma?- How do we risk stratify patients with a new myeloma diagnosis? - What is the role of FISH/karyotype in risk stratification in myeloma?-How do we gauge disease response in myeloma?- How do we define disease progression?- How do we define treatment response? - What is the role of minimal residual disease (MRD) in myeloma? Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In today's episode, we continue our myeloma series, this time we'll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!Content:- Defining MGUS- Discussing risk of progression of MGUS to MM- How to interpret free light chains in renal failure- How do we monitor MGUS patients?- When do we do additional testing in MGUS?- What is smoldering myeloma?- What are myeloma defining events?- How do we risk stratify SM patients?- How do we monitor SM patients? Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myelomahttps://ash.confex.com/ash/2022/webprogram/Paper159606.htmlhttps://ash.confex.com/ash/2022/webprogram/Paper168930.html 2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.https://ash.confex.com/ash/2022/webprogram/Paper170166.htmlLink to the model: https://istopmm.com/riskmodel/ 3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma https://ash.confex.com/ash/2022/webprogram/Paper159357.html 4. Talquetamab: Phase 1/2 results from Monumental-1https://tinyurl.com/kwn9en9mhttps://www.nejm.org/doi/full/10.1056/NEJMoa2204591 5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosishttps://tinyurl.com/yrvjjruv 6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myelomahttps://tinyurl.com/bde84xuw 7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Studyhttps://ash.confex.com/ash/2022/webprogram/Paper159711.html 8. Three excellent abstracts from IstopMM:Is MGUS associated with autoimmune disease?https://tinyurl.com/5dafcz2wIs isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?https://tinyurl.com/4tut3reaIs MGUS associated with CKD?https://tinyurl.com/34swvkj9 9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trialshttps://tinyurl.com/2n78yzfh 10. Surrogacy between PFS and OS in Multiple Myelomahttps://ash.confex.com/ash/2022/webprogram/Paper163855.htmlhttps://pubmed.ncbi.nlm.nih.gov/36495317/

In the first episode in our highly-anticipated multiple myeloma series, we begin our discussion about introduction to testing/workup for plasma cell dyscrasias and having our initial discussion about monoclonal gammopathy of undetermined significance (MGUS). Contents:- What is a plasma cell ?- What is a plasma cell dyscrasia?- What is an "SPEP"?-What is "immunofixation"?-What are "serum free light chains"?-Checking UPEP-Does everyone need a bone marrow biopsy and/or additional workup?-What is MGUS?Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Host: Darryl S. Chutka, M.D. (@ChutkaMD) Guest: Wilson I. Gonsalves, M.D. Monoclonal gammopathies represent abnormal proteins produced by plasma cells. The most common monoclonal gammopathy is monoclonal gammopathy of undetermined significance or MGUS. While MGUS itself is not a malignancy and doesn't require treatment, patients with MGUS have an increased risk of developing a variety of hematologic malignancies and therefore do require surveillance. The topic for today's podcast is monoclonal gammopathy of undetermined significance and our guest is Wilson I. Gonsalves, M.D., a hematologist and oncologist from the Division of Hematology at the Mayo Clinic. We'll discuss how to diagnose MGUS, who is more likely to develop this condition and how patients with it should be followed.  Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Today's guest is Miles Wuller, President and CEO of Ryan Specialty Underwriting Managers, the underwriting arm of Ryan Specialty. As such Miles is responsible for more than 20 MGUs, offering more than 150 lines of business and employing around 550 staff in 27 offices who wrote $2.4bn of Gross Premium in 2021. This means he has a fantastic view of the market and where all its pressure points are to be found. A listen to this podcast will definitely get you right up to speed with all the cut and thrust of US and international specialist lines. But Miles is also a great business builder and manager and in our chat we really get to the heart of the Ryan Specialty modus operandi. For instance, how does Miles keep an incredibly diverse business with multiple brands, housing a huge variety of underwriting entrepreneurs within a core strategic Ryan Specialty identity and culture? Very few executives have to maintain and incentivise innovation and creativity on such a scale while at the same time keeping on top of all the compliance and reporting demands of a major unit of a fast-growing public company. Miles exudes a calm competence at every turn and it is abundantly clear that he thinks really deeply about the industry. For instance his thoughts on the effects of inflation on the sector, cyber insurance, his business's relationship with technology, and the burgeoning hybrid carrier phenomenon are highly insightful. And that's just to mention four topics among many more. Suffice to say that I learnt an awful lot during this interview and I think that you will too. NOTES: A couple of property abbreviations: TIV=Total Insured Values. SOV=Statement of Values Also a request. If anyone can tell me any significant difference between a Managing General Agent (MGA) and a Managing General Underwriter (MGU), please let me know. After 30 years of head-scratching, I think they are completely interchangeable transatlantic versions of each other. LINKS We thank our naming sponsor AdvantageGo: https://www.advantagego.com/ We also thank this Episode's advertising supporter Oxbow Partners https://oxbowpartners.com/

Welcome to Insurance Covered, the podcast that covers everything insurance. In this episode Peter is joined by Richard Clapham, CEO of DUAL, and together they discuss the role of the modern MGA. In this episode we discuss:How the role of an MGA has changed in recent yearsThe difference between MGAs, MGUs, coverholders & delegated authorityThe relationship between an insurer and an MGAHow the DUAL model differs to other MGAsHow MGAs can adapt to survive and thrive in the current market.We hope you enjoyed this episode, if you did please subscribe to stay up to date with future episodes. See acast.com/privacy for privacy and opt-out information.

Dr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.  Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society's Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Bristol Myers Squibb

Blain Murphy is an academic psychologist from Belfast, Northern Ireland. In this episode, we discuss his PhD which investigated the psychological impact of a diagnosis of MGUS on patients' quality of life. It's a real eye opener and a must listen. You can find Blain's paper here: https://www.ejoncologynursing.com/article/S1462-3889(21)00007-7/fulltext. Please leave us a review and share the show on Twitter

Welcome back for another episode of Get Checkered! This week, the girls go over several weekly headlines and do a special on Motor Generator Units (MGUs). Some of the weekly headlines include topics such as the Giovinazzi and Alfa Romeo saga, Mercedes' power unit performance, VW group entering into the F1 engine world, and the GP announcement for Qatar 2021 (and the next 10 years). MGUs have been in the news quite a fair bit lately, so we thought we should dive in and find out more about them. What are they? Why are they so important? Check out this episode to find out.

Dr. Robert Z. Orlowski joins HealthTree Podcast for Multiple Myeloma to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smoldering myeloma. We invite you to join us for this well loved annual show.  Dr. Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center. Dr. Orlowski serves as Chair of the Southwest Oncology Group (SWOG) and is a member of the NCI Steering Committee, the Multiple Myeloma Tissue Bank Steering Committee, the Computerized Provider Order Entry Steering Committee, BMT Committee, and American Society for Biochemistry and Molecular Biology. Dr. Orlowski is on the Editorial Board of Hematology and the Journal of Clinical Oncology. Dr. Orlowski has received many awards over a number of years including the Leukemia & Lymphoma Society Scholar in Clinical Research, the Leukemia & Lymphoma Society's Man of the Year Award, Emil Frei III Award for Excellence in Translational Research from MD Anderson and is the recipient of an ongoing SPORE grant from the NIH. Find news and information from his daily newspaper, Myeloma Daily or find him on Twitter at @myeloma_doc. Thanks to our episode sponsor, Karyopharm Therapeutics

In this episode I cover myeloma.If you want to follow along with written notes on myeloma go to zerotofinals.com/medicine/haematology/myeloma/ or the haematology section in the Zero to Finals medicine book.This episode covers the definitions, pathophysiology, tests, risk factors and treatments of myeloma. The audio in the episode was expertly edited by Harry Watchman.